Physician profile
Anitha Vijayan
NPI 1194741405
$117,986.57
in general payments reported to CMS, 2019-2025
12 companies · $5,561 in 2025
The $5,561 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $12K · 2021: $7,337 · 2022: $9,766 · 2023: $25K · 2024: $30K · 2025: $5,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Education: $14K · Travel and Lodging: $9,290 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,050 · Food and Beverage: $4,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,338.26 |
| Education | $14,220.79 |
| Travel and Lodging | $9,290.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,050.00 |
| Food and Beverage | $4,267.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $33,702.52 | 2019-2025 | Nxstage System One |
| Nxstage Medical, INC. | $33,487.30 | 2019-2025 | Nxstage System One |
| Genzyme Corporation | $20,362.26 | 2019 | |
| Baxter Healthcare | $19,384.50 | 2021-2024 | Renal - Acute |
| Astute Medical, INC. | $5,541.75 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $2,326.64 | 2022-2023 | Tarpeyo |
| Quanta Dialysis Technologies INC | $2,000.00 | 2023 | |
| Horizon Therapeutics Plc | $900.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Travere Therapeutics, INC. | $31.61 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Vijayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.